Drug Profile


Alternative Names: ABI 1648; KRM 1648; PA 1648

Latest Information Update: 20 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaneka
  • Developer ActivBiotics
  • Class Antituberculars; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Chlamydial infections; Helicobacter infections; Intermittent claudication; Leprosy; Mycobacterium avium complex infections; Tuberculosis

Most Recent Events

  • 25 Apr 2013 ActivBiotics completes a phase IIb trial in Chlamydial infections in USA (NCT01631201)
  • 01 Jul 2012 ActivBiotics initiates enrolment in a phase I trial for Chlamydial infections in USA (NCT01631201)
  • 18 Jun 2012 ActivBiotics plans a phase II trial for Chlamydial infections in USA (NCT01631201)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top